Clinical-stage biotechnology company developing oral, microbiome-derived and deuterated short-chain fatty acid therapeutics that modulate immune pathways and regulatory T cells
Clinical-stage biotechnology company developing oral, microbiome-derived and deuterated short-chain fatty acid therapeutics that modulate immune pathways and regulatory T cells. Its pipeline targets psoriasis and other autoimmune and inflammatory diseases, as well as inflammation-associated cancers, including pancreatic and liver cancer.